Signal transducer and activator of transcription 3 limits epstein-barr virus lytic activation in B lymphocytes

Journal of Virology

Volumn 87, Issue 21, 2013, Pages 11438-11446

  Hill, Erik R ^a,h   Kogantil, Siva ^a   Zhi, Jizu ^b   Megyola, Cynthia ^c   Freeman, Alexandra F ^d   Palendira, Umaimainthan ^e   Tangye, Stuart G ^e,f   Farrell, Paul J ^g   Bhaduri McIntosh, Sumita ^a  

^a STONY BROOK UNIVERSITY   (United States)

^b STONY BROOK UNIVERSITY   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

^g IMPERIAL COLLEGE LONDON   (United Kingdom)

^h CAMPBELL UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

STAT3 PROTEIN;

ADOLESCENT; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME REGULATION; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; GAIN OF FUNCTION MUTATION; GENE REPRESSION; HUMAN; HUMAN CELL; INFECTION SENSITIVITY; LOSS OF FUNCTION MUTATION; LYMPHOBLASTOID CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; SCHOOL CHILD; SINGLE CELL ANALYSIS; VIRUS ACTIVATION; VIRUS LATENCY; VIRUS TRANSCRIPTION;

ADOLESCENT; B-LYMPHOCYTES; CELL LINE, TUMOR; CHILD; HERPESVIRUS 4, HUMAN; HOST-PATHOGEN INTERACTIONS; HUMANS; STAT3 TRANSCRIPTION FACTOR; VIRUS ACTIVATION;

EID: 84886886171     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01762-13     Document Type: Article

References (44)

1. Tselis AC, Jenson HB. 2006. Epstein-Barr virus. Taylor & Francis, NY, NY.
2. Hong GK, Gulley ML, Feng WH, Delecluse HJ, Holley-Guthrie E, Kenney SC. 2005. Epstein-Barr virus lytic infection contributes to lymphoproliferative disease in a SCID mouse model. J. Virol. 79:13993-14003.
3. Mueller N, Evans A, Harris NL, Comstock GW, Jellum E, Magnus K, Orentreich N, Polk BF, Vogelman J. 1989. Hodgkin's disease and Epstein-Barr virus. Altered antibody pattern before diagnosis. N. Engl. J. Med. 320:689-695.
4. Pallesen G, Sandvej K, Hamilton-Dutoit SJ, Rowe M, Young LS. 1991. Activation of Epstein-Barr virus replication in Hodgkin and Reed-Sternberg cells. Blood 78:1162-1165.
5. van Esser JW, van der Holt B, Meijer E, Niesters HG, Trenschel R, Thijsen SF, van Loon AM, Frassoni F, Bacigalupo A, Schaefer UW, Osterhaus AD, Gratama JW, Lowenberg B, Verdonck LF, Cornelissen JJ. 2001. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. Blood 98:972-978.
6. Feng WH, Israel B, Raab-Traub N, Busson P, Kenney SC. 2002. Chemotherapy induces lytic EBV replication and confers ganciclovir susceptibility to EBV-positive epithelial cell tumors. Cancer Res. 62:1920-1926.
7. Fu DX, Tanhehco Y, Chen J, Foss CA, Fox JJ, Chong JM, Hobbs RF, Fukayama M, Sgouros G, Kowalski J, Pomper MG, Ambinder RF. 2008. Bortezomib-induced enzyme-targeted radiation therapy in herpesvirusassociated tumors. Nat. Med. 14:1118-1122.
8. Perrine SP, Hermine O, Small T, Suarez F, O'Reilly R, Boulad F, Fingeroth J, Askin M, Levy A, Mentzer SJ, Di Nicola M, Gianni AM, Klein C, Horwitz S, Faller DV. 2007. A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood 109:2571-2578.
9. Bhaduri-McIntosh S, Miller G. 2006. Cells lytically infected with Epstein-Barr virus are detected and separable by immunoglobulins from EBVseropositive individuals. J. Virol. Methods 137:103-114.
10. Gradoville L, Kwa D, El-Guindy A, Miller G. 2002. Protein kinase C-independent activation of the Epstein-Barr virus lytic cycle. J. Virol. 76:5612-5626.
11. Daigle D, Megyola C, El-Guindy A, Gradoville L, Tuck D, Miller G, Bhaduri-McIntosh S. 2010. Upregulation of STAT3 marks Burkitt lymphoma cells refractory to Epstein-Barr virus lytic cycle induction by HDAC inhibitors. J. Virol. 84:993-1004.
12. Yu H, Kortylewski M, Pardoll D. 2007. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat. Rev. Immunol. 7:41-51.
13. Frank DA. 2007. STAT3 as a central mediator of neoplastic cellular transformation. Cancer Lett. 251:199-210.
14. Darnell JE, Jr. 2002. Transcription factors as targets for cancer therapy. Nat. Rev. Cancer 2:740-749.
15. Hui-Yuen J, McAllister S, Koganti S, Hill E, Bhaduri-McIntosh S. 2011. Establishment of Epstein-Barr virus growth-transformed lymphoblastoid cell lines. J. Vis. Exp. 2011:3321. doi:10.3791/3321.
16. Avery DT, Deenick EK, Ma CS, Suryani S, Simpson N, Chew GY, Chan TD, Palendira U, Bustamante J, Boisson-Dupuis S, Choo S, Bleasel KE, Peake J, King C, French MA, Engelhard D, Al-Hajjar S, Al-Muhsen S, Magdorf K, Roesler J, Arkwright PD, Hissaria P, Riminton DS, Wong M, Brink R, Fulcher DA, Casanova JL, Cook MC, Tangye SG. 2010. B cell-intrinsic signaling through IL-21 receptor and STAT3 is required for establishing long-lived antibody responses in humans. J. Exp. Med. 207: 155-171.
17. Ma CS, Chew GY, Simpson N, Priyadarshi A, Wong M, Grimbacher B, Fulcher DA, Tangye SG, Cook MC. 2008. Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3. J. Exp. Med. 205:1551-1557.
18. Holland SM, DeLeo FR, Elloumi HZ, Hsu AP, Uzel G, Brodsky N, Freeman AF, Demidowich A, Davis J, Turner ML, Anderson VL, Darnell DN, Welch PA, Kuhns DB, Frucht DM, Malech HL, Gallin JI, Kobayashi SD, Whitney AR, Voyich JM, Musser JM, Woellner C, Schaffer AA, Puck JM, Grimbacher B. 2007. STAT3 mutations in the hyper-IgE syndrome. N. Engl. J. Med. 357:1608-1619.
19. Rabson M, Heston L, Miller G. 1983. Identification of a rare Epstein-Barr virus variant that enhances early antigen expression in Raji cells. Proc. Natl. Acad. Sci. U. S. A. 80:2762-2766.
20. Schust J, Sperl B, Hollis A, Mayer TU, Berg T. 2006. Stattic: a smallmolecule inhibitor of STAT3 activation and dimerization. Chem. Biol. 13:1235-1242.
21. Tung CP, Chang FR, Wu YC, Chuang DW, Hunyadi A, Liu ST. 2011. Inhibition of the Epstein-Barr virus lytic cycle by protoapigenone. J. Gen. Virol. 92:1760-1768.
22. Batisse J, Manet E, Middeldorp J, Sergeant A, Gruffat H. 2005. Epstein-Barr virus mRNA export factor EB2 is essential for intranuclear capsid assembly and production of gp350. J. Virol. 79:14102-14111.
23. Bhaduri-McIntosh S, Landry ML, Nikiforow S, Rotenberg M, El-Guindy A, Miller G. 2007. Serum IgA antibodies to Epstein-Barr virus (EBV) early lytic antigens are present in primary EBV infection. J. Infect. Dis. 195:483-492.
24. Meydan N, Grunberger T, Dadi H, Shahar M, Arpaia E, Lapidot Z, Leeder JS, Freedman M, Cohen A, Gazit A, Levitzki A, Roifman CM. 1996. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 379:645-648.
25. Yang J, Chatterjee-Kishore M, Staugaitis SM, Nguyen H, Schlessinger K, Levy DE, Stark GR. 2005. Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. Cancer Res. 65:939-947.
26. Countryman JK, Gradoville L, Miller G. 2008. Histone hyperacetylation occurs on promoters of lytic cycle regulatory genes in Epstein-Barr virusinfected cell lines which are refractory to disruption of latency by histone deacetylase inhibitors. J. Virol. 82:4706-4719.
27. Minegishi Y, Saito M, Tsuchiya S, Tsuge I, Takada H, Hara T, Kawamura N, Ariga T, Pasic S, Stojkovic O, Metin A, Karasuyama H. 2007. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature 448:1058-1062.
28. El-Guindy A, Heston L, Miller G. 2010. A subset of replication proteins enhances origin recognition and lytic replication by the Epstein-Barr virus ZEBRA protein. PLoS Pathog. 6:e1001054. doi:10.1371/journal.ppat.1001054.
29. ENCODE Project Consortium. 2011. A user's guide to the encyclopedia of DNA elements (ENCODE). PLoS Biol. 9:e1001046. doi:10.1371/journal.pbio.1001046.
30. Huang DW, Sherman BT, Lempicki RA. 2009. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4:44-57.
31. Schultz DC, Ayyanathan K, Negorev D, Maul GG, Rauscher FJ, III 2002. SETDB1: a novel KAP-1-associated histone H3,lysine 9-specific methyltransferase that contributes to HP1-mediated silencing of euchromatic genes by KRAB zinc-finger proteins. Genes Dev. 16(8):919-932.
32. Chen H, Lee JM, Zong Y, Borowitz M, Ng MH, Ambinder RF, Hayward SD. 2001. Linkage between STAT regulation and Epstein-Barr virus gene expression in tumors. J. Virol. 75:2929-2937.
33. Nepomuceno RR, Balatoni CE, Natkunam Y, Snow AL, Krams SM, Martinez OM. 2003. Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas. Cancer Res. 63:4472-4480.
34. Prang NS, Hornef MW, Jager M, Wagner HJ, Wolf H, Schwarzmann FM. 1997. Lytic replication of Epstein-Barr virus in the peripheral blood: analysis of viral gene expression in B lymphocytes during infectious mononucleosis and in the normal carrier state. Blood 89:1665-1677.
35. Al Tabaa Y, Tuaillon E, Jeziorski E, Ouedraogo DE, Bollore K, Rubbo PA, Foulongne V, Rodiere M, Vendrell JP. 2011. B-cell polyclonal activation and Epstein-Barr viral abortive lytic cycle are two key features in acute infectious mononucleosis. J. Clin. Virol. 52:33-37.
36. Hochberg D, Souza T, Catalina M, Sullivan JL, Luzuriaga K, Thorley-Lawson DA. 2004. Acute infection with Epstein-Barr virus targets and overwhelms the peripheral memory B-cell compartment with resting, latently infected cells. J. Virol. 78:5194-5204.
37. Hislop AD, Annels NE, Gudgeon NH, Leese AM, Rickinson AB. 2002. Epitope-specific evolution of human CD8(+) T cell responses from primary to persistent phases of Epstein-Barr virus infection. J. Exp. Med. 195:893-905.
38. Chen H, Hutt-Fletcher L, Cao L, Hayward SD. 2003. A positive autoregulatory loop of LMP1 expression and STAT activation in epithelial cells latently infected with Epstein-Barr virus. J. Virol. 77:4139-4148.
39. Prince S, Keating S, Fielding C, Brennan P, Floettmann E, Rowe M. 2003. Latent membrane protein 1 inhibits Epstein-Barr virus lytic cycle induction and progress via different mechanisms. J. Virol. 77:5000-5007.
40. Peng H, Zheng L, Lee WH, Rux JJ, Rauscher FJ, III 2002. A common DNA-binding site for SZF1 and the BRCA1-associated zinc finger protein, ZBRK1. Cancer Res. 62:3773-3781.
41. Tangye SG, Cook MC, Fulcher DA. 2009. Insights into the role of STAT3 in human lymphocyte differentiation as revealed by the hyper-IgE syndrome. J. Immunol. 182:21-28.
42. Siegel AM, Heimall J, Freeman AF, Hsu AP, Brittain E, Brenchley JM, Douek DC, Fahle GH, Cohen JI, Holland SM, Milner JD. 2011. A critical role for STAT3 transcription factor signaling in the development and maintenance of human T cell memory. Immunity 35:806-818.
43. Sen N, Che X, Rajamani J, Zerboni L, Sung P, Ptacek J, Arvin AM. 2012. Signal transducer and activator of transcription 3 (STAT3) and survivin induction by varicella-zoster virus promote replication and skin pathogenesis. Proc. Natl. Acad. Sci. U. S. A. 109:600-605.
44. Amarante MK, Watanabe MA. 2009. The possible involvement of virus in breast cancer. J. Cancer Res. Clin. Oncol. 135:329-337.